CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.
May 19th 2022
Despite Latino and Hispanic men being more likely to present with higher-risk prostate cancer, they are less likely to receive treatment for their disease compared to other ethnicities.
May 16th 2022
After experiencing cancer, I feel a profound sense of empathy for others in tough situations, from the war in Ukraine to COVID-19.
May 6th 2022
Treatment with androgen deprivation therapy in combination with Zytiga, docetaxel and prednisone improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
May 3rd 2022
Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.
May 3rd 2022
While a higher risk of heart issues was found in older men years after androgen-deprivation therapy, it is unknown if the risk comes from the treatment or other age-related comorbidities.
April 22nd 2022
From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.
April 15th 2022
The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.
April 8th 2022
From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.
March 28th 2022
A recently FDA-approved drug offers patients with metastatic castration-resistant prostate cancer a newer treatment that improves survival, but is not curative of the disease, which means that more research is needed, according to an expert.
March 23rd 2022
Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.
March 18th 2022
From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.
March 16th 2022
In a news release, Merck advised patients enrolled on the trial to consult with their health care provider regarding their treatment.
March 15th 2022
Regardless of a man’s age, providing care to a partner or family member with cancer has been shown to take a drastic toll on their health. To make matters worse, research shows many men struggle in silence.
March 7th 2022
Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.
February 21st 2022
Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.
February 1st 2022
A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.
January 31st 2022
One expert noted that patients with prostate cancer can take a few months to make an informed treatment decision without impacting their long-term outcomes.
January 18th 2022
The STELLAR-002 trial is currently underway to examine the combination of XL092, an experimental tyrosine kinase inhibitor, in combination with immuno-oncology therapies for patients with advanced solid tumors.
January 17th 2022
Prostate cancer survivors are encouraged to include their partners in interventions to improve sexual function after treatment — and, as study results show, it is better to have these conversations with providers sooner rather than later.
January 11th 2022
Sexual dysfunction may often happen after prostate cancer treatment, and the results of one study shown that an online program for both the patient and their partner may help in this aspect of recovery.
December 23rd 2021
Additional advancements in how radical prostatectomy is performed are needed to improve other urinary outcomes such as good urinary function and social incontinence.
December 3rd 2021
The pharmaceutical company announced preliminary results on a phase 3 trial, which demonstrated that Nubeqa with docetaxel and androgen deprivation therapy may improve overall survival in men with metastatic hormone-sensitive prostate cancer.
December 2nd 2021
With recently revised treatment guidelines, doctors may be more likely to recommend active surveillance to men with low-risk prostate cancer.
November 15th 2021
Hypofractionated radiation for nearly five weeks in men with prostate cancer after surgery may have similar results without added side effects compared with radiation therapy for a standard duration of seven weeks.
November 15th 2021
A man reflects on slight symptoms he was not concerned about leading up to his prostate cancer diagnosis.
October 11th 2021
The first patient was enrolled in a phase 2 clinical trial for the treatment of hormone-sensitive advanced prostate cancer.
October 5th 2021
Treatments for bladder, colorectal and prostate cancer may cause sexual dysfunction in men. Here, an expert provides insight into how patients and survivors may improve their sexual health.
September 26th 2021
It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.
September 25th 2021
In this special issue of CURE®, we spoke with patients and health care providers about fertility issues, treatment advancements and other topics related to kidney, prostate, testicular and bladder cancers.